2. Tajar A., Huhtaniemi I.T., O’Neill T.W. et al. Characteristics of androgen deficiency in late-onset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012; 97(5): 1508–16. https://dx.doi.org/10.1210/jc.2011-2513.

3. Barbonetti A., D’Andrea S., Francavilla S. Testosterone replacement therapy. Andrology. 2020; 8(6): 1551–66.https://dx.doi.org/10.1111/andr.12774.

4. Corona G., Torres L.O., Maggi M. Testosterone therapy: What we have learned from trials. J Sex Med. 2020; 17(3): 447–60.https://dx.doi.org/10.1016/j.jsxm.2019.11.270.

5. Mulhall J.P., Trost L.W., Brannigan R.E. et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018; 200(2): 423–32. https://dx.doi.org/10.1016/j.juro.2018.03.115.

6. Hackett G., Kirby M., Edwards D. et al. British society for sexual medicine guidelines on adult testosterone deficiency, with statements for UK practice. J Sex Med. 2017; 14(12): 1504–23. https://dx.doi.org/10.1016/j.jsxm.2017.10.067.

7. Morales A., Bebb R.A., Manjoo P. et al. Diagnosis and management of testosterone deficiency syndrome in men: Clinical practice guideline. CMAJ. 2015; 187(18): 1369–77. https://dx.doi.org/10.1503/cmaj.150033.

8. Bhasin S., Brito J.P., Cunningham G.R. et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018; 103(5): 1715–44. https://dx.doi.org/10.1210/jc.2018-00229.

9. Yeap B.B., Grossmann M., McLachlan R.I. et al. Endocrine Society of Australia position statement on male hypogonadism (part 1): Assessment and indications for testosterone therapy. Med J Aust. 2016; 205(4): 173–78. https://dx.doi.org/10.5694/mja16.00393.

10. Yeap B.B., Grossmann M., McLachlan R.I. et al. Endocrine Society of Australia position statement on male hypogonadism (part 2): Treatment and therapeutic considerations. Med J Aust. 2016; 205(5): 228–31. https://dx.doi.org/10.5694/mja16.00448.

11. Corona G., Goulis D.G., Huhtaniemi I. et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology. Andrology. 2020; 8(5): 970–87. https://dx.doi.org/10.1111/andr.12770.

12. Salonia A., Bettocchi C., Boeri L. et al.; EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology guidelines on sexual and reproductive health-2021 update: Male sexual dysfunction. Eur Urol. 2021; 80(3): 333–57.https://dx.doi.org/10.1016/j.eururo.2021.06.007.

13. Morgentaler A., Traish A., Hackett G. et al. Diagnosis and treatment of testosterone deficiency: updated recommendations from the Lisbon 2018 international consultation for sexual medicine. Sex Med Rev. 2019; 7(4): 636–49.https://dx.doi.org/10.1016/j.sxmr.2019.06.003.

14. Lunenfeld B., Mskhalaya G., Zitzmann M. et al. Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male. 2021; 24(1): 119–38. https://dx.doi.org/10.1080/13685538.2021.1962840.

15. Qaseem A., Horwitch C.A., Vijan S. et al. Clinical guidelines committee of the american college of physicians. Testosterone treatment in adult men with age-related low testosterone: A clinical guideline from the American College of Physicians. Ann Intern Med. 2020; 172(2): 126–33. https://dx.doi.org/10.7326/M19-0882.

16. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В. с соавт. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021; 18(4): 496–507.

17. Wu F.C.W., Tajar A., Beynon J.M. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010; 363(2): 123–35. https://dx.doi.org/10.1056/NEJMoa0911101.

18. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск (дополненный). Сахарный диабет. 2021; 24(1S): 1–148. (Standards of specialized diabetes care. Ed. by Dedov I.I., Shestakova M.V., Mayorov A.Yu. Sakharny diabet = Diabetes Mellitus. 2021; 24(1S): 1–148 (In Russ.)]. https://dx.doi.org/10.14341/DM12802. EDN: ISOZCM.

19. Zitzmann M., Faber S., Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006; 91(11): 4335–43. https://dx.doi.org/10.1210/jc.2006-0401.

20. Heinemann L.A.J., Zimmermann T., Vermeulen A. et al. A new «aging males» symptoms’ rating scale. Aging Male. 1999; 2: 105–14. https://dx.doi.org/10.3109/13685539909003173.

21. Morley J.E., Charlton E., Patrick P. et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000; 49(9): 1239–42. https://dx.doi.org/10.1053/meta.2000.8625.

22. Smith K.W., Feldman H.A., McKinlay J.B. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf). 2000; 53(6): 703–11. https://dx.doi.org/10.1046/j.1365-2265.2000.01152.x.

23. Corona G., Mannucci E., Petrone L. et al. ANDROTEST: A structured interview for the screening of hypogonadism in patients with sexual dysfunction. J Sex Med. 2006; 3(4): 706–15. https://dx.doi.org/10.1111/j.1743-6109.2006.00262.x.

24. Tajar A., Forti G., O’Neill T.W. et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010; 95(4): 1810–18. https://dx.doi.org/10.1210/jc.2009-1796.

25. Vesper H.W., Bhasin S., Wang C. et al. Interlaboratory comparison study of serum total testosterone

26. Huhtaniemi I.T., Tajar A., Lee D.M. et al. Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men. Eur J Endocrinol. 2012; 166(6): 983–91. https://dx.doi.org/10.1530/EJE-11-1051.

27. Free & Bioavailable Testosterone calculator. URL: http://www.issam.ch/freetesto.htm (date of access – 01.11.2022).

28. Rastrelli G., Corona G., Maggi M. Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction. Asian J Androl. 2020; 22(3): 265–73. https://dx.doi.org/10.4103/aja.aja_61_19.

29. Fiers T., Wu F., Moghetti P. et al. Reassessing free-testosterone calculation by liquid chromatography-tandem mass spectrometry direct equilibrium dialysis. J Clin Endocrinol Metab. 2018; 103(6): 2167–74. https://dx.doi.org/10.1210/jc.2017-02360.

30. Guay A., Miller M.G., McWhirter C.L. Does early morning versus late morning draw time influence apparent testosterone concentration in men aged > or = 45 years? Data from the Hypogonadism In Males study. Int J Impot Res. 2008; 20(2): 162–67.https://dx.doi.org/10.1038/sj.ijir.3901580.

31. Snyder P.J., Bhasin S., Cunningham G.R. et al. Lessons from the testosterone trials. Endocr Rev. 2018; 39(3): 369–86.https://dx.doi.org/10.1056/NEJMoa1506119.

32. Giagulli V.A., Triggiani V., Corona G. et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: Focus on new formulations. Curr Pharm Des. 2011; 17(15): 1500–11.https://dx.doi.org/10.1111/j.1743-6109.2011.02497.x.

33. Grossmann M., Matsumoto A.M. A perspective on middle-aged and older men with functional hypogonadism: Focus on holistic management. J Clin Endocrinol Metab. 2017; 102(3): 1067–75. https://dx.doi.org/10.1210/jc.2016-3580.

34. Corona G., Rastrelli G., Morelli A. et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Men’s Health. 2020; 38(3): 256. https://dx.doi.org/10.1016/j.jsxm.2018.04.641.

35. Cignarelli A., Castellana M., Castellana G. et al. Effects of CPAP on testosterone levels in patients with obstructive sleep apnea: A meta-analysis study. Front Endocrinol (Lausanne). 2019; 10: 551. https://dx.doi.org/10.3389/fendo.2019.00551.

36. Giagulli V.A., Castellana M., Murro I. et al. The role of diet and weight loss in improving secondary hypogonadism in men with obesity with or without type 2 diabetes mellitus. Nutrients. 2019; 11(12): 2975. https://dx.doi.org/10.3390/nu11122975.

37. Bray G.A., Heisel W.E., Afshin A. et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018; 39(2): 79–132. https://dx.doi.org/10.1210/er.2017-00253.

38. Wing R.R., Rosen R.C., Fava J.L. et al. Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 2010; 7(1 Pt 1): 156–65. https://dx.doi.org/10.1111/j.1743-6109.2009.01458.x.

39. Pelusi C., Giagulli V.A., Baccini M. et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: A randomized, double-blind, placebo-controlled study. PLoS One. 2017; 12(9): e0183369.https://dx.doi.org/10.1371/journal.pone.0183369.

40. Krzastek S.C., Smith R.P. Non-testosterone management of male hypogonadism: an examination of the existing literature. Transl Androl Urol. 2020; 9(Suppl 2): S160–S170. https://dx.doi.org/10.21037/tau.2019.11.16.

41. Rastrelli G., Maggi M., Corona G. Pharmacological management of late-onset hypogonadism. Expert Rev Clin Pharmacol. 2018; 11(4): 439–58. https://dx.doi.org/10.1080/17512433.2018.1445969.

42. Giagulli V.A., Castellana M., Lisco G., Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020; 8(6): 1628–41. https://dx.doi.org/10.1111/andr.12850.